AMO Development v. Alcon: Federal Circuit Appeal Voluntarily Dismissed in 65 Days
AMO Development, LLC appealed to the Federal Circuit against Alcon, Inc. and affiliates over US8500724B2, a patent covering laser trephination of the lens capsule and phaco-segmentation. The appeal was voluntarily dismissed just 65 days after filing, with each party bearing its own costs.
A Federal Circuit ophthalmic laser appeal that closed before merits review
AMO Development, LLC — a Johnson & Johnson Vision entity and holder of US8500724B2 — filed this Federal Circuit appeal on 7 February 2023 against Alcon, Inc., Alcon Laboratories, Inc., Alcon Vision, LLC, and Alcon Research, LLC. The patent at issue covers a method and apparatus for patterned plasma-mediated laser trephination of the lens capsule and three-dimensional phaco-segmentation, a technology central to femtosecond laser-assisted cataract surgery (FLACS).
The recorded basis of termination is voluntary dismissal. The docket order states that the motion for voluntary dismissal was granted, the appeal was dismissed, and each party shall bear its own costs. No merits ruling was issued by the Federal Circuit. The specific terms or circumstances that prompted the voluntary dismissal are not disclosed in the available record.
Resolution in 65 days is unusually swift for a Federal Circuit appeal, suggesting the parties reached some understanding — or AMO Development made a strategic decision to withdraw — before full briefing commenced. What drove that decision, and whether any arrangement exists between the parties, is not reflected in the public record.
See Complete Case & Patent Analysis →Filing to Voluntary dismissal in 65 days
65 days — resolved well below the typical Federal Circuit appeal lifecycle
US8500724B2 — Laser Lens Capsule Trephination and 3D Phaco-Segmentation
Any company developing, manufacturing, or commercialising femtosecond laser platforms for cataract surgery — including lens capsule incision systems, phaco-fragmentation tools, or integrated FLACS consoles — should treat US8500724B2 as a priority patent for freedom-to-operate review. The patent's dismissal from the Federal Circuit without a merits ruling means no court has invalidated or narrowed its claims at the appellate level. It remains enforceable as granted.
Official order — verbatim text
The Federal Circuit order grants the motion for voluntary dismissal and closes the appeal without reaching any substantive question of patent validity or infringement. The court's direction that each party bear its own costs is the only dispositive element of the order; no findings, claim constructions, or liability determinations were made. The underlying patent, US8500724B2, emerges from this appeal with its enforceability legally unchanged.
Voluntarily dismissed: what the appeal's withdrawal means for both parties
Voluntary dismissal ends the appeal with no merits ruling
A voluntary dismissal at the Federal Circuit terminates the appeal entirely without the court adjudicating the underlying dispute on the merits. The public record does not specify whether this was dismissal with or without prejudice — the order is silent on that point. Each party bears its own appellate costs as expressly ordered.
No merits adjudicationThe record is silent on prejudice designation
The distinction matters: a dismissal with prejudice bars refiling on the same claims, while one without prejudice potentially leaves the door open. The available record does not specify either. The docket order simply grants the motion and dismisses the appeal. Practitioners should not assume either designation applies without further confirmation from court records.
Prejudice status undisclosedAMO Development withdraws before Federal Circuit review
By voluntarily dismissing, AMO Development forfeits any appellate ruling it may have sought on US8500724B2. The outcome of the underlying district court proceedings — and whatever drove this appeal — remains unaddressed at the Federal Circuit level. The patent itself remains in force; its enforceability is unaffected by this dismissal.
No appellate vindicationAlcon avoids Federal Circuit merits ruling on laser patent
For Alcon and its affiliates, the dismissal means the Federal Circuit never ruled on the patent's validity or the infringement allegations at the appellate level. No cost award was made against them. Whether this reflects a commercial resolution, a strategic concession, or simply AMO Development's reassessment of its appellate prospects is not disclosed in the available record.
Merits dispute unresolvedFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | AMO Development, LLC | Company | /Search in Eureka ↗ |
| Defendant | Alcon, Inc. | Company | /Search in Eureka ↗ |
| Co-Defendant | Alcon Laboratories, Inc. | Company | Search in Eureka ↗ |
| Co-Defendant | Alcon Vision, LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Alcon Research, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Ashley M. Fry | Attorney | Counsel for AMO Development, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Ashley N. Finger | Attorney | Counsel for AMO Development, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Gabriel K. Bell | Attorney | Counsel for AMO Development, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Inge A. Osman | Attorney | Counsel for AMO Development, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Michael A. Morin | Attorney | Counsel for AMO Development, LLCSearch in Eureka ↗ |
| Plaintiff counsel | Roger J. Chin | Attorney | Counsel for AMO Development, LLCSearch in Eureka ↗ |
| Plaintiff law firm | Latham & Watkins, LLP | Law Firm | Representing AMO Development, LLCSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
R&D signals in the femtosecond laser cataract surgery IP space
Forward-looking patent and innovation intelligence derived from the AMO Development v. Alcon dispute over laser lens capsule trephination technology.
AMO Development's FLACS patent filing activity and portfolio depth
AMO Development (J&J Vision) has built a substantial IP position in femtosecond laser-assisted cataract surgery. Tracking continuation filings, CIP applications, and new prosecution activity stemming from the US8500724B2 family reveals where AMO is extending claim coverage in laser capsulotomy and phaco-segmentation — and which adjacent surgical workflow steps remain within their enforcement perimeter.
AMO laser portfolio watchFiling trends in femtosecond laser lens capsule trephination technology
Plasma-mediated laser trephination and computer-guided phaco-segmentation are active innovation areas. Mapping global patent filing trends in this domain — including applicants in Asia and Europe — reveals whether the FLACS technology landscape is consolidating around a few large players or opening up to new entrants in precision ophthalmology hardware and software.
FLACS filing trend analysisAlcon's patent portfolio in laser cataract and phacoemulsification systems
Alcon, Inc. and its research and vision affiliates maintain an extensive IP position in phacoemulsification, laser cataract platforms, and intraocular lens delivery. Analysing Alcon's active filing activity in laser-guided capsulotomy and 3D lens segmentation reveals how their R&D priorities compare to AMO Development's and where competitive patent thickets are forming.
Alcon FLACS IP mapAdjacent R&D white space near laser capsulotomy and segmentation methods
Beyond the core trephination and phaco-segmentation claims covered by US8500724B2, adjacent innovation areas — including AI-guided laser parameter optimisation, real-time OCT integration with FLACS systems, and capsule tension management — may represent lower-density patent territory. These represent potential R&D and filing opportunities for device developers seeking to differentiate in the surgical laser space.
Ophthalmic laser white spaceSimilar Federal Circuit appeals in ophthalmic laser and surgical device patent disputes
Explore Federal Circuit appeal cases involving ophthalmic surgical laser patents and FLACS technology, including voluntary dismissals and infringement disputes in cataract surgery devices.
What this case signals for the ophthalmic laser surgery IP landscape
A swift voluntary Federal Circuit dismissal over a FLACS laser patent raises questions about enforcement posture and portfolio strategy in a competitive cataract surgery market.
FLACS patent enforcement remains commercially sensitive territory
US8500724B2 sits at the heart of femtosecond laser-assisted cataract surgery — a market contested by AMO (J&J Vision) and Alcon. The rapid voluntary dismissal, without a merits ruling, suggests both parties may have interests that are better resolved outside appellate scrutiny. Companies active in FLACS should monitor both parties' patent portfolios closely.
No-cost-award dismissals preserve commercial optionality for both sides
The mutual cost-bearing order avoids financial penalty for either party, which is consistent with a negotiated or strategic withdrawal rather than a clear-cut concession. For IP teams benchmarking enforcement risk in ophthalmic devices, this signals that Federal Circuit disputes in this space can resolve quickly and quietly without establishing precedent.
AMO v Alcon — key questions answered
The Federal Circuit voluntarily dismissed the appeal on 13 April 2023, 65 days after filing. The court granted AMO Development's motion for voluntary dismissal without reaching any merits ruling on the underlying patent dispute. Each party was ordered to bear its own costs. No appellate findings on validity or infringement of US8500724B2 were issued.
The patent at issue is US8500724B2, filed under application number US13/072646. It covers a method and apparatus for patterned plasma-mediated laser trephination of the lens capsule and three-dimensional phaco-segmentation — a core technology in femtosecond laser-assisted cataract surgery (FLACS) platforms.
The available public record does not specify. The Federal Circuit order states only that the motion for voluntary dismissal is granted and the appeal is dismissed, with each party bearing its own costs. The order does not designate the dismissal as with or without prejudice. Practitioners should consult the full docket for any further clarification.
No. A voluntary dismissal at the appellate level — without any merits ruling — does not alter the legal status of the patent itself. US8500724B2 remains in force as granted. No Federal Circuit finding narrowed, invalidated, or otherwise affected the patent's claims through this proceeding.
The defendants are Alcon, Inc. (the primary defendant), Alcon Laboratories, Inc., Alcon Vision, LLC, and Alcon Research, LLC. All four Alcon entities were named as appellees in the Federal Circuit proceeding. AMO Development, LLC — a J&J Vision affiliate — was the appellant and plaintiff.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.